Latest Ratios: P/E Ratio 20.1x · EV/EBITDA 17.0x · ROE 12.3%. (2010–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10.6B | $12.0B | $11.4B | $6.1B | $7.6B | $7.5B | $6.6B | $6.0B | $4.4B | $4.0B | $2.4B |
| Enterprise Value | $10.2B | $11.6B | $11.2B | $6.2B | $7.5B | $7.3B | $6.3B | $5.8B | $4.2B | $3.9B | $2.3B |
| P/E Ratio → | 20.11 | 22.27 | 110.28 | 49.80 | 40.15 | 50.14 | 64.57 | 38.74 | 28.10 | 37.36 | 22.97 |
| P/S Ratio | 3.62 | 4.08 | 4.53 | 3.89 | 7.45 | 7.81 | 8.35 | 7.65 | 6.15 | 6.33 | 4.24 |
| P/B Ratio | 2.37 | 2.62 | 2.73 | 1.53 | 4.13 | 4.30 | 4.37 | 4.28 | 3.70 | 4.16 | 2.88 |
| P/FCF | 18.06 | 20.35 | 28.14 | 36.97 | 73.01 | 34.10 | 48.73 | 59.33 | 35.96 | 37.17 | 18.27 |
| P/OCF | 14.11 | 15.90 | 21.90 | 25.09 | 42.72 | 27.08 | 33.13 | 34.92 | 24.14 | 25.22 | 13.92 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.94 | 4.43 | 3.93 | 7.31 | 7.61 | 8.04 | 7.40 | 5.95 | 6.14 | 4.12 |
| EV / EBITDA | 17.05 | 19.29 | 26.56 | 22.17 | 25.25 | 30.14 | 36.41 | 25.85 | 20.12 | 19.15 | 12.05 |
| EV / EBIT | 21.31 | 18.98 | 50.78 | 30.53 | 31.66 | 37.40 | 54.96 | 32.87 | 24.00 | 23.91 | 15.08 |
| EV / FCF | — | 19.66 | 27.53 | 37.29 | 71.62 | 33.22 | 46.96 | 57.40 | 34.81 | 36.07 | 17.75 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.4% | 67.4% | 58.9% | 65.1% | 74.2% | 75.0% | 72.4% | 77.1% | 77.6% | 76.3% | 76.1% |
| Operating Margin | 16.3% | 16.3% | 6.6% | 8.5% | 22.3% | 17.9% | 14.1% | 21.9% | 23.7% | 25.4% | 27.3% |
| Net Profit Margin | 18.3% | 18.3% | 4.1% | 7.8% | 18.6% | 15.6% | 13.0% | 19.8% | 21.9% | 16.9% | 18.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.3% | 12.3% | 2.5% | 4.2% | 10.6% | 9.2% | 7.0% | 12.0% | 14.5% | 11.9% | 13.5% |
| ROA | 10.2% | 10.2% | 2.0% | 3.4% | 9.4% | 8.2% | 6.4% | 11.0% | 13.2% | 10.7% | 11.8% |
| ROIC | 8.9% | 8.9% | 3.1% | 3.5% | 10.5% | 9.2% | 6.8% | 11.5% | 13.4% | 15.0% | 16.3% |
| ROCE | 10.4% | 10.4% | 3.7% | 4.0% | 12.2% | 10.2% | 7.5% | 13.1% | 15.5% | 17.7% | 19.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.13 | 0.13 | 0.00 | — | — | — | — | — | — |
| Debt / EBITDA | 0.20 | 0.20 | 1.28 | 1.87 | 0.02 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -0.06 | 0.01 | -0.08 | -0.11 | -0.16 | -0.14 | -0.12 | -0.12 | -0.08 |
| Net Debt / EBITDA | -0.68 | -0.68 | -0.59 | 0.19 | -0.49 | -0.80 | -1.37 | -0.87 | -0.66 | -0.58 | -0.35 |
| Debt / FCF | — | -0.69 | -0.61 | 0.32 | -1.38 | -0.88 | -1.77 | -1.93 | -1.15 | -1.10 | -0.51 |
| Interest Coverage | — | — | 52.45 | — | — | — | — | — | — | — | — |
Net cash position: cash ($526M) exceeds total debt ($119M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.26 | 4.26 | 2.54 | 4.88 | 6.18 | 6.17 | 6.80 | 6.17 | 6.56 | 6.67 | 6.43 |
| Quick Ratio | 2.74 | 2.74 | 1.77 | 2.72 | 4.30 | 4.48 | 4.91 | 4.41 | 5.20 | 5.50 | 5.02 |
| Cash Ratio | 1.12 | 1.12 | 1.04 | 1.32 | 2.80 | 3.16 | 3.53 | 2.80 | 3.53 | 4.02 | 3.63 |
| Asset Turnover | — | 0.55 | 0.48 | 0.31 | 0.49 | 0.49 | 0.47 | 0.51 | 0.55 | 0.59 | 0.61 |
| Inventory Turnover | 1.26 | 1.26 | 1.57 | 0.65 | 0.88 | 1.01 | 0.95 | 0.92 | 1.21 | 1.39 | 1.20 |
| Days Sales Outstanding | — | 84.32 | 83.79 | 117.49 | 77.55 | 63.11 | 68.51 | 75.49 | 73.90 | 72.92 | 61.99 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.0% | 4.5% | 0.9% | 2.0% | 2.5% | 2.0% | 1.5% | 2.6% | 3.6% | 2.7% | 4.4% |
| FCF Yield | 5.5% | 4.9% | 3.6% | 2.7% | 1.4% | 2.9% | 2.1% | 1.7% | 2.8% | 2.7% | 5.5% |
| Buyback Yield | 2.8% | 2.5% | 0.8% | 3.7% | 1.9% | 0.0% | 1.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 2.8% | 2.5% | 0.8% | 3.7% | 1.9% | 0.0% | 1.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $137M | $138M | $115M | $103M | $104M | $101M | $102M | $101M | $98M | $96M |
Merger integration execution risk
Based on current market data, GMED trades at a forward P/E of 18.18, which appears to discount the company relative to larger peers like Stryker, likely reflecting investor caution regarding the long-term success of the NuVasive integration and the associated complexity of the combined product portfolio.
The current PEG ratio of 0.71 suggests that the market may be underestimating the company's growth potential relative to its current valuation multiples. Investors should monitor whether the valuation gap narrows as the company demonstrates sustained margin expansion and successful cross-selling of the combined product suite.
As reported in recent financial statements, ROIC has remained modest at 2.9% in 2026Q1, indicating that the company is currently in a phase of capital absorption rather than high-return compounding as it integrates the significant asset base acquired during the recent merger transaction.
The low ROIC relative to historical norms suggests that the company's invested capital is heavily tied up in non-performing or transitional assets. Future improvements in this metric will be a key indicator of whether management can effectively leverage the expanded scale to drive superior returns on invested capital.
According to quarterly filings, the cash conversion cycle remains elevated at 336 days in 2026Q1, primarily driven by a high days-inventory-outstanding of 295 days, which reflects the logistical burden of maintaining extensive surgical set consignments across a broader hospital network post-merger.
This high inventory dependence suggests that the company's efficiency is structurally constrained by the need to support its robotic ecosystem with physical hardware. Investors should monitor whether the company can optimize its field inventory management to release cash and improve overall asset turnover.
The P/E ratio is frequently misapplied to GMED, as it obscures the significant impact of non-recurring merger-related amortization and restructuring charges that artificially depress reported earnings, making the company appear less profitable than its underlying operational cash flow generation would otherwise suggest to a fundamental analyst.
Instead of relying on P/E, investors should prioritize EV/EBITDA or free cash flow yield to better capture the company's true earning power. These metrics provide a clearer view of the business's ability to generate cash after accounting for the heavy capital requirements of its surgical set inventory.
Includes 30+ ratios · 16 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GMED stock.
Globus Medical, Inc.'s current P/E ratio is 20.1x. The historical average is 39.5x. This places it at the 7th percentile of its historical range.
Globus Medical, Inc.'s current EV/EBITDA is 17.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 20.3x.
Globus Medical, Inc.'s return on equity (ROE) is 12.3%. The historical average is 13.6%.
Based on historical data, Globus Medical, Inc. is trading at a P/E of 20.1x. This is at the 7th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Globus Medical, Inc. has 67.4% gross margin and 16.3% operating margin. Operating margin between 10-20% is typical for established companies.
Globus Medical, Inc.'s Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.